Page 1

Alterity THERAPEUTICS Appendix 4C - Q1 FY22 Quarterly Cash Flow Report Highlights : • New details on ATH34 Phase 2 clinical trial released . • • • Data from bioMUSE presented at International Parkinson and Movement Disorder Society Congress . Expanded intellectual property portfolio positions future opportunities . Cash balance as of 30 September 2021 of A $ 41.3M . Quarterly operating cash outflow of $ 4.9M as expected and in - line with clinical trial activity . MELBOURNE , AUSTRALIA AND SAN FRANCISCO , USA - 29 October 2021. Alterity Therapeutics Limited ( ASX : ATH , NASDAQ : ATHE ) ( " Alterity ” or “ the Company " ) , a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions , releases its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 30 September 2021 ( Q1 FY22 ) . The Company's cash position as of 30 September 2021 of $ 41.3M includes A $ 17.2M proceeds from the issue of shares via the approved ATM ( " At the Market " ) facility in July 2021 issued in accordance with ASX Listing Rules 7.1 and 7.1A . Operating cash outflows were A $ 4.9M , which was in line with company expectations and largely due to the preparation for the Phase 2 clinical trial for Alterity's lead drug candidate ATH434 in Multiple System Atrophy ( MSA ) and the bioMUSE ( Biomarkers of Progression in Multiple Systems Atrophy ) natural history . In accordance with ASX Listing Rule 4.7C , payments made to related parties and their associates included in item 6.1 of the Appendix 4C incorporates directors ' fees , consulting fees , remuneration and superannuation at commercial rates . Operational Activities During the quarter , the company progressed the Phase 2 development program for ATH434 . In September , data from the bioMUSE natural history study was presented at the International Parkinson and Movement Disorder Society Congress reporting that advanced MRI methods employed in the study , referred to as quantitative susceptibility mapping ( QSM ) , demonstrated pathological iron accumulation in multiple areas of the brain in patients with early MSA . The study investigators , led by Dr. Daniel Claassen , Associate Professor of Neurology at Vanderbilt University Medical center , concluded that advanced MRI methods for measuring iron may improve patient selection in clinical trials of disease modifying therapy and has potential to serve as a biomarker for assessing treatment induced changes . Most recently , and after the reporting period , Alterity announced that bioMUSE has reached its original enrollment goal and will be expanded to a total of 20 patients with MSA . The study has proved to be invaluable in generating data to inform and de - risk the Phase 2 trial design , and it will continue to provide longitudinal biomarker and clinical data to characterize disease progression in a patient population that mirrors those to be enrolled in the Phase 2 study . Alterity also announced the expansion of the clinical development program for ATH434 . The planned Phase 2 clinical trial is a randomized , double - blind , placebo - controlled investigation of ATH434 in patients with early - stage MSA . The study will explore the effect of ATH434 treatment